The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback